Eli Lilly’s New Vaccine Strategy: What You Need to Know
Eli Lilly’s Strategic Pivot: Why Vaccines Are the Next Frontier In a bold move that signals a major shift in corporate strategy, pharmaceutical giant Eli Lilly has re-entered the vaccine and infectious disease market. By acquiring three private biotech firms—Curevo, LimmaTech Biologics and Vaccine Company—in deals totaling nearly $4 billion, the company is betting that … Read more